Phil H Jones

Phil H Jones is a Senior Group Leader at the Wellcome Sanger Institute and Programme Leader at the MRC Cancer Unit, University of Cambridge. He leads the Jones Group which focuses on understanding how cancer-associated DNA changes in normal stem cells alter their behavior, allowing them to spread through normal tissues—the critical first step toward cancer development.

• Institution: MRC Cancer Unit, University of Cambridge
• Research Program: Cancer, Ageing and Somatic Mutation Programme
• Professional Recognition: Fellow of the Royal Society, Fellow of the Academy of Medical Sciences

Dr. Jones's research centers on how mutations that alter the competitive fitness of normal stem cells give mutant stem cells the ability to spread through normal tissues. His current work employs deep sequencing, advanced imaging, gene editing, and single-cell analysis to define how oncogenic mutations alter stem cell behavior during aging and the earliest stages of cancer development in skin and esophagus. His lab-based studies complement his clinical work at Addenbrooke's Hospital, where he treats patients with non-melanoma skin cancer.

Analysis of his recent publications reveals a consistent focus on somatic mutations in normal epithelial tissues, particularly examining how specific mutations (such as those in p53, Notch1, and PIK3CA) confer competitive advantages to cells, enabling clonal expansion. His work demonstrates that normal tissues become extensively colonized by mutant cells with age, with some mutations increasing cancer risk while others may actually decrease it. A key finding across multiple publications is that mutant clones can outcompete and eliminate early-stage tumors, suggesting novel approaches to cancer prevention.

• Fellow of the Royal Society
• Fellow of the Academy of Medical Sciences
• Multiple high-impact publications in Nature, Science, and Cell journals

Dr. Jones collaborates extensively with Cancer Research UK, the Department of Oncology at the University of Cambridge, and the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. His research is highly translational, aiming to apply fundamental discoveries about somatic evolution in normal tissues to develop rational interventions that reduce cancer risk in high-risk patients. The Jones Group employs a multidisciplinary approach combining experimental biology with computational modeling to understand the evolutionary dynamics of mutant clones in aging tissues.

The Jones Group operates within the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute, utilizing advanced 3D culture methods, gene editing, live imaging, and single-cell analysis capabilities. Their research infrastructure supports studies of both skin epidermis and esophageal epithelium, with particular focus on how lifestyle factors (sun exposure, alcohol consumption) and aging influence the somatic mutation landscape of normal tissues.